🔎 Trials Near Me

Beranda › Kanker Metastatik › Virginia › Richmond

Uji klinis Kanker Metastatik di Richmond, VA

12 studi untuk Kanker Metastatik mencari peserta di lokasi sekitar Richmond (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Menerima pesertaFase 2
  • VCU Massey Cancer Center at Stony Point, Richmond
  • VCU Massey Comprehensive Cancer Center, Richmond
Semua usia · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT05564377

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Menerima pesertaFase 3
  • Virginia Cancer Institute, Richmond
  • Virginia Cancer Institute, Richmond
  • Virginia Cancer Institute, Mechanicsville · 6 mi jauhnya
  • dan 2 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07222800

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Menerima pesertaFase 3
  • Research Site, Midlothian · 11 mi jauhnya
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07647328

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Menerima pesertaFase 3
  • VCU Health Adult Outpatient Pavillion, Richmond
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Menerima pesertaFase 2
  • VCU Massey Comprehensive Cancer Center, Richmond
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06311214

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Menerima pesertaFase 2
  • Virginia Commonwealth University Massey Cancer Center, Richmond
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06769698

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Menerima pesertaFase 3
  • Research Site, Richmond
Usia 18 ke atas · Wanita · Diperbarui 29 Jul 2026 · NCT07044336

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Menerima pesertaFase 3
  • Bon Secours St. Francis Medical Oncology Center, Midlothian · 11 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT06757634

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Menerima pesertaFase 2/3
  • Virginia Commonwealth University, Richmond
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Apr 2026 · NCT06947928

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Menerima pesertaFase 3
  • VCU Massey Cancer Center, Richmond
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Apr 2026 · NCT06064877

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Menerima pesertaFase 2/3
  • Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond
Usia 18 ke atas · Pria · Diperbarui 8 Apr 2026 · NCT04787744

Uji klinis Kanker Metastatik di kota lain

Studi lain di Richmond

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.